l c interview, page-35

The thing is... the phase 1b results when first announced (although light on detail) were pretty dam good.

9/10 ten responders, with no safety issues at all - for these very ill patients with a nasty metastasized cancer.

5 of which were partial responses, but as I said the other day, one can see a reduction of 95% of their cancer and still be classed as a partial response. Partial being anywhere between greater than 30% and less than 100% (in imu's case).

But the average asx investor doesn't seem to understand how good these figures are (as opposed to the UK and US for example). But maybe it's because in Australia investors haven't seen a massive biotech win, like we have in the UK and US.

So on good news the sp drifted from 2.1c down to 1.6c.

Even some well informed investors like Money Mozart sold out on the news.

But now the data will be presented to the world, big pharma and maybe the press. There will also be more details and more data given. As we now have a complete responder and another greater than 30% responder, it appears as though the patients are still getting better. That's massive, especially as still being alive is a bonus for these seriously ill cancer patients. And still no safety issues.

Being selected for presentation is a big deal. Viralytics were too, and look what happened to them (taken over by Merck for over $50om).

But imu's technology and platform is so much bigger and more significant than Viralytics was/is (no offense to Viralytics, and I was a shareholder of them too).

Viralytics offered an improvement on two T cell therapy, Imugene offer a completely new and safer generation to all T cell therapies.

cheers